

NOVARTIS ACCESS-TO-MEDICINE PROJECTS 2006

Project	Objective	Target region	Value (USD millions)	Patients reached
Malaria/WHO ¹	Provide <i>Coartem</i> at cost for public sector use	Africa, Asia, Latin America	179	33 000 000
Leprosy/WHO ²	Eliminate leprosy by providing free medications to all patients worldwide, with WHO, through 2010	Global	4	226 000
Tuberculosis ²	Donation of fixed-dose combinations	Tanzania, Sri Lanka	3	134 000
Novartis Institute for Tropical Diseases (NITD) ³	Discover novel treatments and prevention methods for major tropical diseases; NITD discoveries to be available in poor endemic countries without profit	Developing countries	11	-
Novartis Foundation for Sustainable Development ³	Work at policy and field level to improve access to healthcare for the world's poorest people	Developing countries	7	95 000
Patient Assistance Programs (PAP) ² ; excl. <i>Gleevec/Glivec</i>	Assistance to patients experiencing financial hardship, without third-party insurance coverage for their medicines	US	129	155 000
<i>Gleevec</i> US PAP ²	Within capability of Novartis, continue to ensure access for patients in the US who cannot afford the drug	US	55	3 500
<i>Glivec</i> Global PAP ²	Within capability of Novartis, continue to ensure access for patients outside the US who cannot afford the drug	Global (excluding US)	362	15 000
Together Rx Access	Discount program for the uninsured	US	1	15 000
Emergency Relief ²	Support major humanitarian organizations	Global	4	-
Total			755	33.6 million

¹ During 2006, Novartis shipped 62 million *Coartem* treatments for public sector use. Of these shipments, an estimated 33 million treatments actually reached patients by year-end, based on preliminary analysis of local distribution. Value of the *Coartem* program in 2006 was calculated using the number of treatments shipped and the ex-factory price of *Coartem* to private-sector purchasers in malaria-endemic developing countries, minus payments to Novartis to cover costs under terms of the public-private partnership with WHO. These payments were received through WHO, UNICEF and other procurement agencies, acting on behalf of governments and other public sector institutions in developing countries eligible to receive *Coartem* at the "not-for-profit" price.

² Ex-factory price to private market

³ Operating costs